Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company
Vectura's CEO James Ward-Lilley and incoming CFO from Skyepharma, Andrew Derodra, sat down with Scrip and explained where they see the excitement, synchronization and R&D fusion for the larger company.
You may also be interested in...
In an interview with Scrip, Sterna Biologicals CEO Christian Pangratz says that the small German company has a number of options available to advance its Phase II projects in asthma, COPD, ulcerative colitis and atopic dermatitis.
Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.